Technical Analysis for ISEE - IVERIC bio, Inc.

Grade Last Price % Change Price Change
C 6.37 -4.64% -0.31
ISEE closed down 4.64 percent on Tuesday, May 11, 2021, on 1.54 times normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical ISEE trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
50 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 3 Days in a Row Weakness -4.64%
Slingshot Bullish Bullish Swing Setup -7.28%
NR7 Range Contraction -7.28%
Wide Bands Range Expansion -7.28%
Older End-of-Day Signals for ISEE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Resistance about 12 hours ago
Fell Below 20 DMA about 12 hours ago
20 DMA Support about 18 hours ago
Down 2 % about 18 hours ago
Down 1% about 18 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


IVERIC bio, Inc. Description

IVERIC bio, Inc., formerly Ophthotech Corporation, is a biopharmaceutical company. The Company is focused on the discovering and developing of novel gene therapy solutions to treat orphan inherited retinal diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. The Company’s BEST1 gene encodes a multifunctional protein known as bestrophin1, that regulates ion transport and intracellular calcium signaling in retina cells and helps maintain homeostasis in the sub retinal space between photoreceptors and the retinal pigment epithelial (RPE) cells. Its IC-200 is a mutation independent gene therapy, delivered by an AAV2 vector.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diseases Eye Emerging Technologies Gene Therapy Macular Degeneration Ophthalmology Related Macular Degeneration Retina Blindness Vision Age Related Macular Degeneration Gene Therapy Of The Human Retina Retinal Disease Macula Of Retina Retinal Diseases Visual System Disorder Homeostasis

Is ISEE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 7.98
52 Week Low 3.56
Average Volume 504,096
200-Day Moving Average 5.92
50-Day Moving Average 6.33
20-Day Moving Average 6.52
10-Day Moving Average 6.87
Average True Range 0.34
ADX 19.05
+DI 24.59
-DI 25.33
Chandelier Exit (Long, 3 ATRs ) 6.38
Chandelier Exit (Short, 3 ATRs ) 6.65
Upper Bollinger Band 7.39
Lower Bollinger Band 5.66
Percent B (%b) 0.41
BandWidth 26.53
MACD Line 0.17
MACD Signal Line 0.19
MACD Histogram -0.0158
Fundamentals Value
Market Cap 570.55 Million
Num Shares 89.6 Million
EPS 1.53
Price-to-Earnings (P/E) Ratio 4.17
Price-to-Sales 0.00
Price-to-Book 2.75
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.08
Resistance 3 (R3) 7.15 6.97 6.96
Resistance 2 (R2) 6.97 6.79 6.94 6.92
Resistance 1 (R1) 6.67 6.68 6.59 6.61 6.88
Pivot Point 6.50 6.50 6.46 6.47 6.50
Support 1 (S1) 6.20 6.32 6.11 6.13 5.86
Support 2 (S2) 6.02 6.20 5.99 5.82
Support 3 (S3) 5.72 6.02 5.78
Support 4 (S4) 5.66